Table 3.

OR (95% CI) for association of glucosinolate intake and prostate cancer in strata of genetic polymorphisms in the EPIC-Heidelberg nested case-control study (n = 740)

GenotypeCases/controlsCrude OR* (95% CI)PinteractionAdjusted OR (95% CI)Pinteraction
per 10 mg/d increment of glucosinolate intake
GSTM1
    pres/pres19/470.98 (0.52-1.83)1.24 (0.51-3.03)
    pres/del103/1740.95 (0.70-1.28)0.82 (0.55-1.22)
    del/del126/2700.74 (0.55-0.99)0.380.67 (0.45-0.98)0.30
    ≥1del229/4440.82 (0.67-1.02)0.570.74 (0.56-0.97)0.84
    ≥1pres122/2210.96 (0.73-1.25)0.150.92 (0.65-1.29)0.12
GSTT1
    pres/pres88/1630.99 (0.71-1.38)0.89 (0.57-1.38)
    pres/del116/2520.78 (0.59-1.04)0.70 (0.48-1.02)
    del/del44/770.75 (0.42-1.36)0.530.78 (0.38-1.58)0.73
    ≥1del160/3290.78 (0.61-1.01)0.250.74 (0.54-1.02)0.42
GSTM1/GSTT1
    0 or 1 del54/900.88 (0.58-1.32)0.85 (0.50-1.42)
    2 del92/2061.21 (0.90-1.64)1.14 (0.75-1.72)
    3 or 4 del102/1950.61 (0.43-0.87)0.010.56 (0.35-0.87)0.01
GSTP1
    AA125/2160.82 (0.61-1.09)0.87 (0.61-1.26)
    AG95/2280.85 (0.61-1.18)0.68 (0.44-1.05)
    GG28/481.06 (0.59-1.90)0.620.82 (0.38-1.81)0.64
    ≥1G123/2760.89 (0.68-1.18)0.630.73 (0.50-1.05)0.81
GSTA1
    GG68/1480.73 (0.48-1.12)0.63 (0.38-1.05)
    GA132/2470.83 (0.63-1.10)0.89 (0.62-1.29)
    AA48/970.93 (0.62-1.40)0.850.80 (0.44-1.46)0.81
    ≥1A180/3440.86 (0.69-1.08)0.810.87 (0.64-1.17)0.90
NQO1
    CC163/3330.72 (0.55-0.95)0.64 (0.44-0.91)
    CT80/1331.04 (0.77-1.42)1.04 (0.69-1.55)
    TT5/260.81 (0.24-2.78)0.111.94 (0.03-127.27)0.22
    ≥1T85/1591.02 (0.76-1.38)0.040.98 (0.66-1.46)0.10

NOTE: Pinteraction for test of interaction between glucosinolate intake and genotype.

  • *OR calculated by unconditional logistic regression adjusted for matching variables (time of recruitment and 5-year age group).

  • Additionally adjusted for family history of prostate cancer and vegetable intake.